Read the March 2019 issue of Pharmafocus online now!
pharmafile | February 26, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Cancer, Drug pricing, HIV, Trump, WHO, brexit, depression, mental health, pharmacovigilance, rare disease
Just one month to go until Brexit here in the UK, and it’s still all to play for. After months of warning the government over its need for certainty post-Brexit, the pharma and life sciences industries are nonetheless left with little option other than to keep one eye on the daily news and one set of fingers crossed. While the issue seems forever poised to eclipse all other concerns, there is good news elsewhere this month.
President Trump used his platform at the State of the Union Address in February to announce the ambitious goal to eliminate HIV by 2030 – a welcome commitment which falls in line with similar pledges from the UK Government and the WHO. He also refreshed his vow to lower drug prices, and promised an additional $500 million investment to children with cancer; you can read the full story on our front page.
Elsewhere in the issue, you can also read about the latest research from the University of Edinburgh which has identified over 200 genes linked to depression. The findings could mean big things for the field down the line, and you can read exclusive comment from Professor Andrew McIntosh, the study’s first author, on page 8.
In our monthly features, we also delve into the latest R&D developments in the field of cancer, including a technique which turns tumour cells into harmless fat and even the promise from one biotech of a cure for all cancers within a year – you can read all about them on page 20. We also have a full-length feature on the crucial role played by pharmacovigilance in tackling the future’s challenges of uncertainty, while Dan Jeffries shares his remarkable story as one of the few patients in the UK living with not one, but two rare diseases!
Related Content
Intra-Cellular Therapies shares phase 3 results for major depressive disorder therapy
Intra-Cellular Therapies has announced positive topline results from Study 501, which assessed lumateperone 42mg as …
Geneos Therapeutics shares data from phase 1/2 trial for cancer vaccine
Geneos Therapeutics has announced that it has published positive safety, immunogenicity and efficacy data from …
Curve Therapeutics’ CSO publishes research on HIF inhibition for cancer treatment
Curve Therapeutics has announced that its chief scientific officer, Professor Ali Tavassoli has published research …
